Cargando…

The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

Tumor-targeted CD40 agonism represents an attractive strategy for cancer immunotherapy (CIT) as it promotes dendritic cell (DC) activation and concomitant tumor-specific T cell priming without causing systemic side effects. We developed the bispecific CD40 agonistic antibody CEA-CD40, which triggers...

Descripción completa

Detalles Bibliográficos
Autores principales: Sum, Eva, Rapp, Moritz, Dürr, Harald, Mazumdar, Alekhya, Romero, Pedro J, Trumpfheller, Christine, Umaña, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928381/
https://www.ncbi.nlm.nih.gov/pubmed/35292514
http://dx.doi.org/10.1136/jitc-2021-003264